Four lots of IGIV were investigated for anti-hepatitis B surface antibody (anti-HBs) content and all were found to contain significant antibody titer. Moreover, IGIV that was administered to four bone marrow transplant recipients for medical purposes unrelated to HBV transmission produced protective anti-HBs titers in all. These studies suggest IGIV may be useful for HBV prophylaxis in the appropriate setting or if HBIG is unavailable. The optimum regimen for HBV prevention in distinct transplant settings needs to be determined.
Iatrogenic transmission of hepatitis B virus (HBV) has decreased secondary to effective blood donor screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) and increased immunization with hepatitis B vaccine. Nevertheless, transmission and occasionally reactivation of HBV have remained significant problems in the transplant setting.
1,2 The short-and long-term risks of HBV transmission from a donor may be accepted because of a shortage of donor tissues. Moreover, transplant recipients considered to be immune to HBV on the basis of resolved acute infection may reactivate virus producing HBsAg and detectable viral DNA. 3 Cytotoxic chemotherapy alone can infrequently cause reactivation of HBV replication with significant hepatitis. ful in other transplant settings and we sought to determine if administration of passive antibody to BMT recipients could result in protective levels. We evaluated two available sources of antibody including intramuscular HBIG, which may be contraindicated in patients with thrombocytopenia. An intravenous formulation of anti-HBs would be ideal, but is not presently available and therefore we evaluated IGIV as a source of antibody to HBV. IGIV can be easily administered and has been used to treat a variety of infectious and autoimmune complications in the transplant setting. 5 The titer of anti-HBs in several commercial lots of IGIV as well as the titer of anti-HBs in the serum of nonimmune patients following infusion of IGIV for unrelated medical purposes was determined.
Patients and methods
The patient was a 43-year-old male with stable phase CML awaiting allogeneic bone marrow transplantation. His only HLA-identical match was a HBsAg-positive sibling. The patient was negative for both anti-HBs and HBsAg and despite receiving four doses of recombinant HB vaccine, no anti-HBs could be detected. In an attempt to prevent infection with HBV, the patient received 10 ml of HBIG (Abbott, Chicago, IL, USA) each day for 5 days prior to infusion of the donor's bone marrow cells. The i.m. injections were discontinued when the patient became thrombocytopenic. A single dose of IGIV was administered on day 14, to provide an alternative source of passive antiHBs. The patient died of interstitial lung disease 30 days after bone marrow transplant. The post-mortem examination revealed organizing diffuse alveolar damage with focal areas of hemorrhage. The liver histopathology was completely normal. At the time of his demise, his serum HBsAg was negative and no HBV DNA was detected by PCR.
IGIV as a source of anti-HBs was determined by titer in four random lots of IGIV: three lots contained 10% IG (Gamimune N, 10% immune globulin intravenous (human), Miles, West Haven, CT, USA), and the fourth lot contained 5% IG (Alpha Therapeutics, Los Angeles, CA, USA). To determine further if patients were developing anti-HBs from routine administration of IGIV, we assessed the antiHBs titer of four additional patients receiving IGIV for unrelated indications. Patients were chosen at random and factors that could affect serum antibody levels, such as severity of intercurrent illness, hydration, catabolic state, GI or urinary loss of protein were not taken into account. Doses of IGIV ranged from 250 mg/kg to 300 mg/kg. The anti-HBs titers were determined by RIA (AUSAB; Abbott). The IU/l was calculated according to Hollenger et al. 6 All patients were documented to lack HBsAg and anti-HBs prior to IGIV therapy. Anti-HBs titer was determined on the day of receipt of the last IGIV dose and in one case 3 days later.
Results
The titer of anti-HBs in our patient's serum was determined as a function of HBIG (10 ml/day for 7 days) and subsequently IGIV (400 mg/kg once) administration ( Figure  1 ). The patient's anti-HBs titer on admission was 0. Following administration of a total of 20 ml of HBIG over the first 48 h the patient's anti-HBs titer rose to 14 IU/l. Treatment with a total of 70 ml HBIG over the first 7 days resulted in a serum level of 455 IU/l by day 12. Additional administration of IGIV on day 14 produced a titer of 490 IU/l on day 16. With no further Ig administration the titer declined to 310 IU/l by day 22.
The titer of anti-HBs measured in four lots of IGIV is presented in Table 1 . The first three lots of 10% IG had titers ranging from 1460-1890 IU/l and a fourth lot containing 5% IG had a titer of 840 IU/l.
The doses and timing of IGIV therapy administered to four patients for illness unrelated to HBV are shown in Table 2 . All patients developed significant anti-HBs titers that ranged from 64 IU/l in a patient who received a single infusion of 300 mg/kg to 205 IU/l in a patient who received 3 consecutive days of therapy at a dose of 250 mg/kg/day. All patients were anti-HBsAg seronegative before initiation of therapy. Day 0 is used to denote the day that serum anti-HBs titers were sampled in relation to day of IGIV doses.
Discussion
Transmission or reactivation of HBV following transplantation is not infrequent and leads to increased morbidity and mortality. 7, 8 Transmission of donor virus and reactivation of HBV in the recipient have in some series resulted in poor outcome. 2 In a review of 2586 BMT recipients, 24 received HBsAg+ marrow, resulting in severe liver failure and death in 21% of these patients compared to an overall 3.7% mortality rate. 9 Reactivation of hepatitis B has been reported at 6 to 21 months after BMT in patients with chronic GVHD, suggesting that chronic GVHD and immunosuppressive drugs may permit symptomatic HBV reactivation in previously HBsAb-positive patients. 10, 11 HBV can infect bone marrow stromal cells and bone marrow colony-forming cells in vitro. 12, 13 A recent report demonstrates infection of PBMC in vivo.
14 It has been suggested that these cells may represent an extrahepatic site of viral persistence and therefore a potential source of transmission.
Fortunately, it has been demonstrated that both active and passive immunization against HBV can prevent transmission of virus following occupational exposures, in the neonate following birth to an infected mother, upon transfusion of HBV contaminated blood and in infected liver transplant recipients. This suggests that adequate titers of anti-HBs could be effective in preventing HBV infection in the BMT setting.
An anti-HBs titer Ͼ10 IU/l, achieved by active immunization or HBIG prophylaxis (0.06 ml/kg × 1 or 2), is considered to provide adequate protection to healthy persons upon blood or a body fluid exposure to HBV. 15 Approximately 10-fold more HBIG is required to prevent trans-mission following transfusion of one unit of HBsAg-positive blood to a naive recipient. 16 Moreover, transmission of HBV to the transplanted liver of an immunosuppressed chronic HBV carrier has been diminished by maintenance of very high titer anti-HBs in a range Ͼ100 IU. The practice of maintaining high titer anti-HBs has resulted in decreased morbidity and mortality in recipients of liver allograft with HBV. [17] [18] [19] These results demonstrate the efficacy of high titer antibody in preventing de novo infection and modulating virus replication in chronically infected individuals.
The optimum titer and duration of anti-HBs antibody needed to prevent transmission of HBV in the BMT recipient is unknown and requires systematic study. The use of HBIG in the allogeneic BMT setting has been described. 11, 20 The efficacy of these interventions however remains unclear as neither the viral load of the donor nor the anti-HBs titers of the recipients were assessed prior to treatment. In addition, our efforts to administer HBIG highlighted the difficulty of repeated administration of intramuscular therapy to patients that are thrombocytopenic and neutropenic with augmented risks of local bleeding and infection.
An intravenous formulation of HBV Ig is not currently available. IGIV as an alternative source of anti-HBs and determination of serum anti-HBs levels to guide administration of passive immunization has not previously been evaluated in the BMT setting. As a practical approach to prevent transmission of HBV from a known positive donor, pending formal study, we propose that passive immunization of the BMT recipient should be attempted. Although active immunization should proceed in the pretransplant period, the response rate as with our patient, is likely to be low and cytoablative therapy at the time of transplant may result in rapid loss of titers. Close monitoring is appropriate and passive immunization will likely be indicated, irrespective of prior immune status. Our case indicated that HBIG or IVIG can produce anti-HBs titers Ͼ100 IU/l which is in excess of those suggested to prevent or diminish transmission of virus after transfusion of a unit of infected blood or after liver transplantation to an HBV+ recipient. At 30 days post-transplant our patient, whose titer remained Ͼ100 IU/l to day 22 had no measurable HBV RNA by PCR.
The studies accompanying this report further demonstrate that certain lots of IGIV have titers of anti-HBs that may be used to transfer protective antibody in the appropriate setting when HBIG is unavailable. However, since the donor plasma used to prepare IGIV is not selected to contain anti-HBs, the concentration of a specific antibody may vary. An intravenous formulation of HBIG, if available, would be preferable to IGIV with regard to constancy of titer and decreased volume of fluid infusion. Taken together, these results showed that in addition to HBIG, IGIV provided high titer antibodies to HBsAg that exceeded established protective level. The use of IGIV in the peritransplant setting to prevent HBV transmission/reactivation may be of considerable utility.
